Richard Lee

Mr. Richard Lee

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
RLRichard Lee
Richard Lee
KSKirti Sad
Kirti Sad
DFDorelle V. Fawwal
Dorelle V. Fawwal
JSJennifer M Spangle
Jennifer M Spangle
Breast cancer pathogenesis, treatment, and patient outcomes are shaped by tumor-intrinsic genomic alterations that divide breast tumors into molecular subtypes. These molecular subtypes often dictate viable therapeutic interventions and, ultimately, patient outcomes. However, heterogeneity in therapeutic response may be a result of underlying epigenetic features that may further stratify breast cancer patient outcomes. In this review, we examine non-genetic mechanisms that drive functional changes to chromatin in breast cancer to contribute to cell and tumor fitness and highlight how epigenetic activity may inform the therapeutic response. We conclude by providing perspectives on the future of therapeutic targeting of epigenetic enzymes, an approach that holds untapped potential to improve breast cancer patient outcomes.

6 December 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RJRobert B. Jones
Robert B. Jones
JFJonathan Farhi
Jonathan Farhi
MAMiranda Adams
Miranda Adams
KPKiran K. Parwani
Kiran K. Parwani
GCGarrett W. Cooper
Garrett W. Cooper
JSJennifer M Spangle
Jennifer M Spangle
The high frequency of aberrant PI3K pathway activation in hormone receptor–positive (HR+) breast cancer has led to the development, clinical testing, and approval of the p110α-selective PI3K inhibitor alpelisib. The limited clinical efficacy of alpelisib and other PI3K inhibitors is partially attributed to the functional antagonism between PI3K and estrogen receptor (ER) signaling, which is mitigated via combined PI3K inhibition and endocrine therapy. We and others have previously demonstrated chromatin-associated mechanisms by which PI3K supports cancer development and antagonizes ER signaling through the modulation of the H3K4 methylation axis, inhibition of KDM5A promoter H3K4 demethylation and KMT2D/MLL4-directed enhancer H3K4 methylation. Here we show that inhibition of the H3K4 histone methyltransferase MLL1 in combination with PI3K inhibition impairs HR+ breast cancer clonogenicity and cell proliferation. While combined PI3K/MLL1 inhibition reduces PI3K/AKT signaling and H3K4 methylation, MLL1 inhibition increases PI3K/AKT signaling through the dysregulation of gene expression associated with AKT activation. These data reveal a feedback loop between MLL1 and AKT whereby MLL1 inhibition reactivates AKT. We show that combined PI3K and MLL1 inhibition synergizes to cause cell death in in vitro and in vivo models of HR+ breast cancer, which is enhanced by the additional genetic ablation of the H3K4 methyltransferase and AKT target KMT2D/MLL4. Together, our data provide evidence of a feedback mechanism connecting histone methylation with AKT and may support the preclinical development and testing of pan-MLL inhibitors.Significance: Here the authors leverage PI3K/AKT-driven chromatin modification to identify histone methyltransferases as a therapeutic target. Dual PI3K and MLL inhibition synergize to reduce clonogenicity and cell proliferation, and promote in vivo tumor regression. These findings suggest patients with PIK3CA-mutant, HR+ breast cancer may derive clinical benefit from combined PI3K/MLL inhibition.

9 June 2025 in Mayo Clinic Proceedings: Digital Health
Verified
Journal Article
Open access
ARArya S. Rao
Arya S. Rao
SPSiona Prasad
Siona Prasad
RLRichard Lee
Richard Lee
SFSusan Farrell
Susan Farrell
SMSophia McKinley
Sophia McKinley
MSMarc D. Succi
Marc D. Succi
To develop and validate an artificial intelligence–powered platform that simulates surgical oral examinations, addressing the limitations of traditional faculty-led sessions. This cross-sectional study, conducted from June 1, 2024, through December 1, 2024, comprised technical validation and educational assessment of a novel large language model (LLM)–based surgical education tool (surgery oral examination large language model [SOE-LLM]). The study involved 12 surgical clerkship students completing their core rotation at a major academic medical center. The SOE-LLM, using MIMIC-IV–derived surgical cases (acute appendicitis and pancreatitis), was implemented to simulate oral examinations. Technical validation assessed performance across 8 domains: case presentation accuracy, physical examination findings, historical detail preservation, laboratory data reporting, imaging interpretation, management decisions, and recognition of contraindicated interventions. Educational utility was evaluated using a 5-point Likert scale. Technical validation showed the SOE-LLM’s ability to function as a consistent oral examiner. The model accurately guided students through case presentations, responded to diagnostic questions, and provided clinically sound responses based on MIMIC-IV cases. When tested with standardized prompts, it maintained examination fidelity, requiring proper diagnostic reasoning and differentiating operative versus medical management. Student evaluations highlighted the platform’s value as an examination preparation tool (mean, 4.250; SEM, 0.1794) and its ability to create a low-stakes environment for high-stakes decision practice (mean, 4.833; SEM, 0.1124). The SOE-LLM shows potential as a valuable tool for surgical education, offering a consistent and accessible platform for simulating oral examinations.

13 June 2023 in Preprints.org
Verified
Preprint
Open access
RLRichard Lee
Richard Lee
KSKirti Sad
Kirti Sad
DFDorelle V. Fawwal
Dorelle V. Fawwal
JSJennifer M Spangle
Jennifer M Spangle
Breast cancer pathogenesis, treatment, and patient outcomes are shaped by tumor-intrinsic genomic alterations that divide breast tumors into molecular subtypes. These molecular subtypes often dictate viable therapeutic interventions, and ultimately, patient outcomes. However, heterogeneity of therapeutic response may be a result of underlying epigenetic features that may further stratify breast cancer patient outcomes. In this review we examine non-genetic mechanisms that drive functional changes to chromatin in breast cancer to contribute to cell and tumor fitness, and highlight how epigenetic activity may inform therapeutic response. We conclude by providing perspectives on the future of therapeutic targeting of epigenetic enzymes, an approach which holds untapped potential to improve breast cancer patient outcomes.

12 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKirti Sad
Kirti Sad
CJCelina Yvonne Jones
Celina Yvonne Jones
DFDorelle V Fawwal
Dorelle V Fawwal
EHEmily J Hill
Emily J Hill
KSKatie Skinner
Katie Skinner
JSJennifer M Spangle
Jennifer M Spangle
Sequencing of human patient tumors has identified recurrent missense mutations in genes encoding core histones. We report that mutations that convert histone H3 amino acid 50 from a glutamate to a lysine (H3E50K) support an oncogenic phenotype in human cells. Expression of H3E50K is sufficient to transform human cells as evidenced by a dramatic increase in cell migration and invasion, and a statistically significant increase in proliferation and clonogenicity. H3E50K also increases the invasive phenotype in the context of co-occurring BRAF mutations, which are present in patient tumors characterized by H3E50K. H3E50 lies on the globular domain surface in a region that contacts H4 within the nucleosome. We find that H3E50K perturbs proximal H3 post-translational modifications globally and dysregulates gene expression, activating the epithelial to mesenchymal transition. Functional studies using S. cerevisiae reveal that, while yeast cells that express H3E50K as the sole copy of histone H3 show sensitivity to cellular stressors, including caffeine, H3E50K cells display some genetic interactions that are distinct from the characterized H3K36M oncohistone yeast model. Taken together, these data suggest that additional histone H3 mutations have the potential to be oncogenic drivers and function through distinct mechanisms that dysregulate gene expression. Summary: Recurrent missense mutation that alter histone H3E50 were identified in patient tumors H3E50K expression dysregulates global H3 post-translational modification, gene expression and may govern a transcriptional program associated with metastatic phenotypes hht2-E50K yeast cells exhibit growth defects in the presence of DNA damaging agents

4 April 2023
Verified
Other
Open access
RJRobert B. Jones
Robert B. Jones
JFJonathan Farhi
Jonathan Farhi
MAMiranda Adams
Miranda Adams
KPKiran K. Parwani
Kiran K. Parwani
GCGarrett W. Cooper
Garrett W. Cooper
JSJennifer M Spangle
Jennifer M Spangle
The high frequency of aberrant PI3K pathway activation in hormone receptor–positive (HR+) breast cancer has led to the development, clinical testing, and approval of the p110α-selective PI3K inhibitor alpelisib. The limited clinical efficacy of alpelisib and other PI3K inhibitors is partially attributed to the functional antagonism between PI3K and estrogen receptor (ER) signaling, which is mitigated via combined PI3K inhibition and endocrine therapy. We and others have previously demonstrated chromatin-associated mechanisms by which PI3K supports cancer development and antagonizes ER signaling through the modulation of the H3K4 methylation axis, inhibition of KDM5A promoter H3K4 demethylation and KMT2D/MLL4-directed enhancer H3K4 methylation. Here we show that inhibition of the H3K4 histone methyltransferase MLL1 in combination with PI3K inhibition impairs HR+ breast cancer clonogenicity and cell proliferation. While combined PI3K/MLL1 inhibition reduces PI3K/AKT signaling and H3K4 methylation, MLL1 inhibition increases PI3K/AKT signaling through the dysregulation of gene expression associated with AKT activation. These data reveal a feedback loop between MLL1 and AKT whereby MLL1 inhibition reactivates AKT. We show that combined PI3K and MLL1 inhibition synergizes to cause cell death in in vitro and in vivo models of HR+ breast cancer, which is enhanced by the additional genetic ablation of the H3K4 methyltransferase and AKT target KMT2D/MLL4. Together, our data provide evidence of a feedback mechanism connecting histone methylation with AKT and may support the preclinical development and testing of pan-MLL inhibitors.Significance:Here the authors leverage PI3K/AKT-driven chromatin modification to identify histone methyltransferases as a therapeutic target. Dual PI3K and MLL inhibition synergize to reduce clonogenicity and cell proliferation, and promote in vivo tumor regression. These findings suggest patients with PIK3CA-mutant, HR+ breast cancer may derive clinical benefit from combined PI3K/MLL inhibition.